Contact

Sendabio with the help of Abra Invest closes investment round


Integral service around a transaction
BY : Diego GutiérrezApril Thu, 2015
In April 2015, the Basque biotechnology Sendabio has closed an investment round with an industrial partner. This capital injection will enable it to tackle its growth plan with the internationalisation of its products, initially in Latin America. Sendabio has been advised by Abra Invest for the successful completion of the operation.

 

Sendabio: food supplements with the active ingredient DHA

SendaBio, S.L., a company created at the end of 2012 for the research, development, manufacture and marketing of pharmaceutical and dietetic products, mainly food supplements with the active ingredient DHA, aims to be a national and international reference in the sector of food supplements based on DHA, as well as in secondary sectors comprising other types of products, such as food, clinical nutrition, pets, ......

The origin of the company comes from numerous investigations carried out over the last 15 years to achieve the purest and most bioavailable Omega 3 DHA on the market, currently having one of the best active ingredients based on DHA and the only one with minimum levels of phytanic acid, which allows it to have a greater impact on people's health and wellbeing.

SendaBio aims to develop, manufacture and market products based on its high added value DHA for application in the cardiovascular, neurology, ophthalmology, pregnancy and lactation, obesity and weight control, sports medicine, clinical nutrition, oncology,.....

Abra Invest has advised Sendabio on the transaction.

Guillermo Ibeas Alonso has been the Abra Invest partner in charge of leading the advisory services to Sendabio in the process of capital raising or strategic investor. Sendabio was looking for an investor that would not only provide financing for growth but could also support it with other synergies. In the end, the investor was an important industrial group that has backed Sendabio as part of its process of diversification for the penetration capacity of its products and its management team.

Julen Galarza leads the expert team managing Sendabio

Julen Galarza is the founder and CEO of Sendabio. Graduated from ETSII in Bilbao and trained through 5 specialised Masters, Julen has more than 20 years of international experience in companies such as Ribate, Ormazabal Group and ML Group.

Sendabio's team is a global team of experts in the development of pharmaceutical and dietetic products at national and international level, accumulating more than 20 years of experience in research and development, with an intellectual property result and international patent on PhA-free DHA, with more than 60 product innovations in biomedical, pharmaceutical and food applications.

 

Other posts you may be interested in

List of acquisitions in medical device biotechnology

Operations Biotechnology February 2015

New developments in biotech funds in Spain

 

 

The M&A Professionals

Meet our services

MEET
OUR
METODOLOGY

Do you want to be up to date?

SUSCRIBE OUR NEWSLETTER

Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?

M&A NEWS
INDUSTRIAL REPORTS
closearrow-circle-o-downchevron-downcrossmenu